Current Management of Disseminated Germ Cell Tumors.

This article reviews the evidence supporting its use as well as common alterations based on prognostic grouping or contraindications to bleomycin. Special topics around the management of intermediate/poor prognosis choriocarcinoma and brain metastases are included. The management of residual masses for both seminoma and nonseminoma is discussed as well as long-term follow-up care of patients. Finally, the management of relapsed disseminated GCT is addressed. PMID: 31277732 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/31277732?dopt=Abstract

Source: The Urologic Clinics of North America - July 7, 2019 Category: Urology & Nephrology Authors: Lavoie JM, Kollmannsberger CK Tags: Urol Clin North Am Source Type: research